What is Wize Pharma?
Wize Pharma, Inc. is a biopharmaceutical entity operating at the clinical stage, with its primary focus directed towards the development and commercialization of treatments for ophthalmic conditions, notably Dry Eye Syndrome (DES). The company has strategically in-licensed rights to LO2A, a compound already registered and marketed in Germany, Switzerland, Hungary, and the Netherlands for DES and related ophthalmological illnesses such as CCh and Sjögren's syndrome. This positions Wize Pharma to leverage existing market penetration and regulatory approvals in key European markets as it seeks to expand its therapeutic offerings.
How much funding has Wize Pharma raised?
Wize Pharma has raised a total of $7.5M across 1 funding round:
Other Financing Round
$7.5M
Other Financing Round (2020): $7.5M, investors not publicly disclosed
What's next for Wize Pharma?
The recent major strategic investment signals a pivotal phase for Wize Pharma, likely enabling the company to accelerate its clinical development pipeline, expand its commercialization efforts for LO2A, and potentially explore new therapeutic avenues within ophthalmology. This infusion of capital is expected to bolster research and development initiatives, support regulatory submissions in new territories, and strengthen its market presence. The company's focus on a significant unmet need in ophthalmic care, coupled with existing product registrations, suggests a trajectory geared towards scaling operations and achieving broader market impact.
See full Wize Pharma company page
